JPMorgan: 'Solid quarter with Mounjaro upside' JPMorgan was impressed by Eli Lilly's results and noted that the company's update indicates more upside ahead
So happy I found them
The art of tissue-specific and disease-specific dosing may emerge in the not-too-distant future: Rather than using the current pharmacologic doses of GLP-1s to soak receptors throughout the body, we may learn how to apply much more tailored brush strokes to effectively treat, say, dementia or rheumatoid arthritis
Anybodys aches are indirect and not a direct effect of the drug
Growth hormone's counter-regulatory effects necessitate vigilance for glycemic deterioration
(Official FDA prescribing information for the T2D indication: confirms same six dose strengths 2.5, 5, 7.5, 10, 12.5, 15mg and identical titration interval as Zepbound.) Jastreboff AM, Aronne LJ, Ahmad NN, et al